Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Ultragenyx stock crashed Thursday, losing almost half its value, after its experimental Angelman treatment failed in final-phase testing. The post Ultragenyx Crashes, On Deck To Hit A Record Low, On A Shocking Failure appeared first on Investor’s Business Daily.
TG Therapeutics is Wednesday’s IBD Stock Of The Day. Shares of the multiple sclerosis biotech has topped an early entry and is near a breakout. The post IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy…
Uniqure stock wavered Wednesday after the Food and Drug Administration accepted its application for approval of a Huntington’s gene therapy. The post UniQure’s Embattled Huntington’s Gene Therapy Clears A Key Hurdle appeared first on Investor’s Business Daily.
Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies. The post Why Novartis Just Surged 6%, Eyeing A Breakout appeared first on Investor’s Business Daily.
Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients. The post One Of Amgen’s Biggest Moneymakers Cuts The Risk Of Dying By 20% appeared first on…
Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. The post Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers appeared first on Investor’s Business Daily.
Amgen and AstraZeneca’s drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S. The post Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent? appeared first on Investor’s Business Daily.
Revolution Medicines won FDA approval Wednesday for the pancreatic cancer treatment that once caused its stock to skyrocket. The post FDA Approves ‘Unprecedented’ Pancreatic Cancer Drug appeared first on Investor’s Business Daily.
Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing. The post Spyre Plunges, While This Setback Isn’t Shaking Analysts appeared first on Investor’s Business Daily.
Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer. The post Jazz Sparks On Its New Plan To Take On Roche; Hint: It’s In Cancer appeared first…
